Conrado Guerrero Quiles

Dr. Conrado Guerrero Quiles


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RSRekaya Shabbir
Rekaya Shabbir
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
BLBrian Lane
Brian Lane
LZLeo Zeef
Leo Zeef
PHPeter J. Hoskin
Peter J. Hoskin
TSTim Smith
Tim Smith
Introduction: Hypoxic cancers are radioresistant, but biomarkers based on expression of multiple genes can identify patients who will benefit from hypoxia modification. Most studies identifying relevant genes exposed cells in culture to 1% oxygen, which activates hypoxia-inducible factor (HIF). However, oxygen concentrations in hypoxic tumours are heterogeneous ranging from <0.1%. As lower oxygen levels would likely affect transcriptional responses, we aimed to investigate how gene selection at different oxygen levels affects the genes identified and their prognostic capability. Methods: Four MIBC (J82, T24, UMUC3, HT1376) and two non-MIBC (RT4, RT112) bladder cancer cell lines were exposed to varying oxygen levels (20%, 1%, 0.2% and 0.1% O2) for 24 h and were then harvested and frozen. RNA was extracted and transcriptomes analysed using Clariom S microarrays. Differences in gene expression were investigated. Prognostic and predictive significance of a published 24-gene signature was compared with one generated from genes identified at lower oxygen levels. Results: The number of upregulated genes increased with decreasing O2 level. The number of biological pathways involved also increased. Differences between cell lines dominated those due to hypoxia. Some genes were commonly upregulated in MIBC and NMIBC cells and others increased exclusively in either MIBC or NMIBC cells. The median expression of a published 24-gene bladder cancer hypoxia-associated signature increased with decreasing oxygen levels. Seventy-seven genes were upregulated in at least three cell lines by exposure to 0.1% O2. The median expression of the 77 genes was of borderline prognostic significance in the bladder cancer cohort in the TCGA (The Cancer Genome Atlas). Five of the seventy-seven genes upregulated by hypoxia were present in the twenty-four-gene bladder hypoxia signature. The median expression of the 5 genes demonstrated identical prognostication to the 24-gene signature but failed to predict benefit from hypoxia modification. Conclusions: The number of genes upregulated by exposure of bladder cancer cells to hypoxia increases as O2 level is decreased from 1% to 0.2% to 0.1%. Differential upregulation of gene expression by MIBC and NMIBC cells and the associated biological pathways may be useful in understanding the genetics of bladder cancer invasiveness. Based on a search of the literature, this is the first study that assessed the expression of genes in bladder cancer using three hypoxic concentration levels to identify biomarkers for disease progression and prognosis among differentially expressed bladder cancer genes.

28 July 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
SFSiobhan Fahy
Siobhan Fahy
MBMatej Bartak
Matej Bartak
JAJulia Gonzalez Abalos
Julia Gonzalez Abalos
EPEmilia Powell
Emilia Powell
XXXxxxx Xxxxxx
Xxxxx Xxxxxx
Muscle-invasive bladder cancer (MIBC) is a prevalent disease that can be treated with radiotherapy, but has a poor prognosis. Radiation-induced extracellular matrix (ECM) remodelling and fibrosis can induce tumour resistance and recurrence, but have not been studied in MIBC. Here, we aimed to characterise the impact of radiation on the ECM composition of MIBC. Three MIBC cell lines (T24, UMUC3, J82) were treated with fractionated radiation. We used proteomics to analyse the ECM composition produced by surviving cancer cells and immunofluorescence to investigate changes in the morphology and number of ECM fibres. We evaluated the RNA expression of identified ECM proteins (FN1, COL5A1, COL1A1, TNF6AIP6, FLG) in one cystectomy (TCGA-BLCA, n=397) and two radiotherapy (BC2001, n=313; BCON, n=151) cohorts. There were 613 proteins affected by radiation (padj2 or <-2), 68 of which were ECM-associated proteins. There was a general increase in proteases and protease regulators but heterogeneity across cell lines. Enrichment analysis showed ECM organisation was the primary pathway affected. Immunofluorescence confirmed radiation affected ECM structure, generally, reducing the number, length and width of fibres. Five ECM genes of interest were identified (COL1A1, COL5A2, FN1, FLG, TNFAIP6), constituting an ECM signature. High FN1, COL1A1, TNF6AIP6 mRNA levels and ECM signature scores were independent poor prognostic markers, while FLG mRNA expression independently predicted radiotherapy benefit in a meta-analysis (n=861). We found high COL1A1 expression levels predicted hypoxia-modifying treatment benefit. Prognostic significance of COL5A2, FN1 and the ECM signature was dependent on patients harbouring TP53-mutations. Radiation alters the composition and structure of the ECM produced by MIBC. As a proof-of-concept, we showed that radiation-affected ECM genes are independent prognostic and predictive markers of radiotherapy benefit in MIBC. Future studies should validate these radiation-induced ECM changes in clinical samples, and explore the role of FLG in radioresistance.

4 April 2025 in bioRxiv
Verified
Preprint
Open access
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
AGA. Julia Gonzalez
A. Julia Gonzalez
AFA. S. Foussat
A. S. Foussat
AOA. Olympitis
A. Olympitis
TLT. Lodhi
T. Lodhi
CWCatharine Mary Louise West
Catharine Mary Louise West
Our overarching aim was to determine how hypoxia affects the extracellular matrix (ECM). Transcriptomic analysis (21,941 patients; 10 cancer types) identified ECM remodelling as the predominant pathway affected by hypoxia. Multi-omics confirmed that hypoxia impacts ECM organisation and collagen degradation; 53 ECM genes were affected, of which 74% were HIF1/HIF2-regulated. Spatial transcriptomics highlighted different hypoxia remodelling processes in tumour and stroma. Five ECM genes commonly affected in tumour and in vitro constituted a signature. This signature was independently prognostic and independently predictive of radiotherapy benefit in multiple malignancies. Patients within either high or low hypoxic-ECM score tertiles benefited from radiotherapy versus surgery. Hypoxic ECMs generated in vitro increased adhesion and decreased migration of cancer cells, an effect enhanced by irradiation. Immunofluorescence demonstrated that hypoxia decreased collagen fibre number, and irradiation decreased cell-ECM interactions. Taken together, these findings demonstrate hypoxia induces pan-cancer ECM changes, directly impacting radiotherapy benefit.

1 April 2026 in Communications Medicine
Verified
Journal Article
Open access
PDF file
HAHanan Abumanhal-Masarweh
Hanan Abumanhal-Masarweh
SASalam A. Assi
Salam A. Assi
XLXinming Liu
Xinming Liu
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
TLTaha Lodhi
Taha Lodhi
MHMarilena Hadjidemetriou
Marilena Hadjidemetriou
Background: Radiotherapy induces systemic changes beyond the targeted tumour site, yet the biological mechanisms driving these effects remain poorly understood. This study aims to longitudinally profile acute systemic plasma proteomic responses to radiotherapy in patients with prostate, bladder, and head and neck cancers, providing insight into shared and tumour-specific effects and identifying biomarkers predictive of treatment-related toxicities. Methods: We apply our previously developed Nano-proteomics workflow to comprehensively analyse longitudinal weekly plasma samples collected before and during radiotherapy. We perform mass spectrometry-based differential protein analysis to identify acute changes of the plasma proteome and enriched biological pathways involved. In the prostate cohort, we associate plasma proteomics with clinical toxicity outcomes. Results: Our data indicate that the most significant systemic proteomic changes occur within the first two weeks of radiotherapy, highlighting a critical period for biomarker identification. Across all patient cohorts, we observe common biological responses: rapid activation of inflammatory and immune pathways, followed by structural reorganisation and immune resolution, regardless of tumour type or concurrent treatments. Despite this shared acute response, distinct protein mediators are found to be dysregulated in a tumour-specific manner. In the prostate cancer cohort, plasma profiling at baseline, one week after the initiation of radiotherapy, and at the end of radiotherapy, results in the identification of 28, 29, and 20 proteins, respectively, that are associated with subsequent bowel and urinary toxicities. Conclusions: This study underscores the value of longitudinal proteomics in uncovering systemic effects of radiotherapy and supports the potential of plasma proteomic biomarkers to identify patients at increased risk of radiotherapy-induced toxicity, paving the way for personalised treatment strategies.

5 August 2025 in Proteomes
Verified
Journal Article
Open access
PDF file
FAFaris Alanazi
Faris Alanazi
ASAmmar Sharif
Ammar Sharif
MKMelissa Kidd
Melissa Kidd
EKEmma-Jayne Keevill
Emma-Jayne Keevill
VBVanesa Biolatti
Vanesa Biolatti
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
Background Plasma membrane proteins (PMPs) play key roles in cell signalling, adhesion, and trafficking, and are attractive therapeutic targets in cancer due to their surface accessibility. However, their typically low abundance limits detection by conventional proteomic approaches. Methods: To improve PMP detection, we employed a surface proteomics workflow combining cell surface biotinylation and affinity purification prior to LC-MS/MS analysis in cervical (SiHa) and bladder (UMUC3) cancer cell lines cultured under normoxic (21% O2) or hypoxic (0.1% O2) conditions. Results: In SiHa cells, 43 hypoxia-upregulated proteins were identified exclusively in the biotin-enriched fraction, including ITGB2, ITGA7, AXL, MET, JAG2, and CAV1/CAV2. In UMUC3 cells, 32 unique upregulated PMPs were detected, including CD55, ADGRB1, SLC9A1, NECTIN3, and ACTG1. These proteins were not observed in corresponding whole-cell lysates and are associated with extracellular matrix remodelling, immune modulation, and ion transport. Biotinylation enhanced the detection of membrane-associated pathways such as ECM organisation, integrin signalling, and PI3K–Akt activation. Protein–protein interaction analysis revealed links between membrane receptors and intracellular stress regulators, including mitochondrial proteins. Conclusions: These findings demonstrate that surface biotinylation improves the sensitivity and selectivity of plasma membrane proteomics under hypoxia, revealing hypoxia-responsive proteins and pathways not captured by standard whole-cell analysis.

15 March 2026 in Clinical Oncology
Verified
Journal Article
Open access
TLT. Lodhi
T. Lodhi
MRM. Reardon
M. Reardon
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
ARA.M. Rojas
A.M. Rojas
ACA. Choudhury
A. Choudhury
PHP. Hoskin
P. Hoskin
High-dose-rate brachytherapy boost (HDR-BTb) combined with external beam radiotherapy (EBRT) improves biochemical relapse-free survival (bRFS) in localised prostate cancer (PCa) yet ∼21% of patients relapse despite dose escalation. Hypoxia and angiogenesis biomarkers have been linked to treatment outcomes through immunohistochemistry (IHC) but genomic validation at the transcriptomic level remains lacking. This study hypothesised that hypoxia- and angiogenesis-related gene expression profiles could predict clinical benefit from HDR-BTb escalation, refining patient selection. Whole transcriptome analysis using Clariom S microarrays was conducted within a phase III single-centre randomised controlled trial comparing EBRT alone versus EBRT+HDR-BTb. Primary and secondary endpoints were bRFS, metastasis-free survival (MFS), and overall survival (OS). Expression of CD34, SLC2A1, HIF1A, and SPP1 was evaluated alongside established 28- and 32-gene hypoxia signatures. Composite interaction terms combining high/low gene expression assessed joint biomarker effects. Statistical analyses included log-rank tests and Cox proportional hazards models performed using R (R Core Team, 2024). Differentially expressed genes (DEGs) and pathway enrichment analyses were obtained in EBRT and HDR-BTb patients with or without relapse. Eighty-one men (EBRT+HDR-BTb = 39; EBRT = 42) were analysed (median follow-up: 131 months). High HIF1A and CD34 expression were prognostic for worse MFS (P = .01) and bRFS (P = .04), respectively. SPP1 and the 32-gene signature were associated with worse OS (P = .02). Predictive analysis showed HDR-BTb benefit in patients with low HIF1A (P = .004), low SLC2A1 (p = 0.04), low 32-gene scores (p = 0.047), and high CD34 (p = 0.02). A significant SLC2A1-CD34 interaction predicted HDR-BTb benefit (P = .017). In relapsed HDR-BTb patients, nine DEGs were identified and enriched for muscle and immune-related pathways, distinct from the 62 DEGs seen in the EBRT cohort, with no overlap. Gene expression had limited prognostic value, and relapse DEGs differed by treatment. Low SLC2A1, high CD34, and their interaction predicted HDR-BTb benefit. These findings support biomarker-led stratification using hypoxia-related signatures in PCa.